Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 2 - The Real Truth

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report

Bristol-Myers Squibb is set to release its third-quarter results by the end of this month, and analysts expect a notable double-digit drop in earnings.

Barchart

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Benzinga

How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?

Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.

Barchart

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year.

Benzinga

Is Wall Street Bullish or Bearish on Bristol-Myers Stock?

While Bristol-Myers Squibb has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

Bristol Myers Squibb Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions.

Benzinga

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report

Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.

Barchart

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Although Bristol-Myers Squibb has outshined relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Bristol-Myers Stock?

Bristol-Myers has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report

Bristol-Myers Squibb is poised to announce its first-quarter results this month, and analysts predict a triple-digit growth in the company’s bottom-line figure.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Bristol-Myers Stock Outperforming the Dow?

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

StockNews.com

3 Healthcare Stocks Tackling America’s Biggest Medical Challenges

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

StockNews.com

3 Precision Medicine Stocks That Could Transform Healthcare

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine industry is expected to witness significant growth and expansion. Hence, it could be wise to invest in quality precision medicine stocks Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) that are transforming…

MarketBeat

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 High-Conviction Stocks with Strong Buy Ratings from Analysts

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

Barchart

What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

Barchart

Earnings Preview: What To Expect From Bristol-Myers Squibb's Report

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth dip in the company’s bottom-line figure.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

StockNews.com

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

Barchart

Is Bristol-Myers Squibb Stock Outperforming the Nasdaq?

Although Bristol-Myers Squibb has outperformed the broader Nasdaq index over the past three months, analysts remain cautious about its growth prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.